PhreesiaPHR +4.81%65 EBITDA Margin % is 12.97% as of Apr. 2026. GuruFocus rates PHR with a GF Score™ of 65/100 and a GF Value™ of $26.97 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Phreesia ranks worse than 54.34% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Phreesia's EBITDA for the
three
months ended in Apr. 2026 was $17.0 Mil. Phreesia's Revenue for the
three
months ended in Apr. 2026 was $130.9 Mil. Therefore, Phreesia's EBITDA margin for the quarter that ended in Apr. 2026 was 12.97%.
Phreesia (NYSE:PHR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Phreesia EBITDA Margin % Related Terms
Phreesia EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Phreesia's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHR vs HSTM, WEAV, EVH: EBITDA Margin % Comparison
For the Health Information Services subindustry, Phreesia's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phreesia EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Phreesia's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phreesia (PHR) has a EBITDA Margin % of 12.97% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Phreesia and its competitors. According to the industry distribution chart, Phreesia ranks #363 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 54.3%.
Is Phreesia's EBITDA Margin % too high?
Phreesia's current EBITDA Margin % is 12.97%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Phreesia's value of 12.97% is 27% above this industry median. Based on the distribution chart, Phreesia ranks #363 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Phreesia has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Phreesia's EBITDA Margin % compare to HSTM and WEAV?
According to the Healthcare Providers & Services industry distribution chart, Phreesia ranks #363 out of 668 companies for EBITDA Margin %. This places Phreesia in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Phreesia's value of 12.97% is 27% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phreesia's current EBITDA Margin % of 12.97% is 27% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Phreesia and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phreesia's current EBITDA Margin % is 12.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phreesia stock overvalued right now?
Based on GuruFocus' analysis, Phreesia (PHR) is currently considered Possible Value Trap. The stock's GF Value™ is $26.97, compared to a current price of $9.59 — trading 64.4% below its estimated fair value. The current EBITDA Margin % is 12.97% and 27% above the Healthcare Providers & Services industry median of 10.21. Phreesia's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Phreesia (PHR), the current EBITDA Margin % is 12.97% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phreesia (PHR) Overvalued in 2026?
Based on GuruFocus' analysis, Phreesia stock appears to be undervalued.
The current stock price of $9.59 is trading 64.4% below its estimated GF Value™ of $26.97.
GuruFocus considers Phreesia to be Possible Value Trap.
Key valuation signals for PHR:
EBITDA Margin %: 12.97%
GF Value™: $26.97 vs. price of $9.59 (64.4% below fair value)
Industry Position: 27% above the Healthcare Providers & Services median (#363 of 668)
No single metric tells the full story. See the PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
65GF Score
Get the complete analysis for PHR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHR has been successfully added to your 
